MYDECINE
Revolutionizing Natures Medicine for Mental Health & Vitality
Revolutionizing Nature's Medicine
for Mental Health & Vitality

About Us


Mydecine Innovations Group™️ is a publicly traded life sciences parent company dedicated to the development and production of adaptive pathway medicine, natural health products and digital health solutions.

Mydecine’s experienced cross functional teams have the dynamic capabilities to oversee all areas of medicine development including synthesis, genetic research, import/export, delivery system development, clinical trial execution,through to product commercialization and distribution. By leveraging strategic partnerships with scientific, medical, military, and clinical organizations, Mydecine™️ is positioned at the forefront of psychedelic medicine naturally derived from fungi, therapeutic solutions, and fungtional™️ mushroom vitality products.

Our portfolio of unified companies, including Mydecine Health Sciences™️, Mindleap Health™️, and NeuroPharm™️ focus on providing innovative and effective options that can provide millions of people with a healthier quality of life.
Mydecine Health Sciences Logo
NeuroPharm Inc.™️ (NPI) is developing a unique and proprietary set of pharmaceutical and natural health products addressing mental wellness in vulnerable populations.
Learn MoreLearn More
Mindleap Health™️ is an advanced digital health platform that helps people connect with mental health specialists who can empower them to thrive and develop habits for a healthy mind.
Mydecine’s spore-to-sale™️ operational extension of the Company, Mydecine Health Sciences™️ (“MHS”), is taking a two-pronged approach and focusing on both psychedelic (clinical) and fungtional™️ (consumer) avenues of commercializing fungi.
Learn More

Our Portfolio

Natural Health Products
Learn More→
We are discovering, extracting, and combining powerful fungtional© and psychedelic ingredients in mushrooms to balance and enhance the brain.
Research & Development
We are charting new paths with Neurological Disorder Medicines based on the novel compounds found in psychedelic medicines.
Learn More→
Learn More→Digital Health Solutions
We are developing breakthrough digital technologies to augment mental healthcare with data, digital therapeutics, and global connectivity.

Our Story

We started Mydecine Innovations Group™️ with the goal of revolutionizing the way people live and experience life by offering cutting edge natural products and technologies. Our international team has been described as a collection of passionate business leaders, scientists, mental health professionals and technology visionaries.

We are inspired by the future, the innovators, the dreamers; and our products embody this  spirit. They are built for those that aspire to be healthy physically and spiritually while living life to the fullest and daring to disrupt the norm.

Our passion sent us on a mission to develop high quality products and disruptive new technologies so we can contribute to making the world a better place.

For Investors

Ticker Symbols
CSX: MYCO
OTC: MYCOF
FSE: 0NFA
SEDAR ProfileInvestor Presentation
1d
5d
1m
6m
ytd
1y
5y
See All News →

Mydecine Innovations Group Announces The Official Mindleap Health Mobile App Launch in IOS and Android Stores

September 30, 2020
Mindleap's digital telehealth mobile application for mental coaching and wellbeing is now available for download.
Read More →

New App, Mindleap, Aims To Revolutionize Psychedelic Use And Wellness

September 24, 2020
High Times article details a new Mindleap app that connects mental health professionals with people using psychedelics.
Read More →

Mindleap Launches Digital Platform Intended For Psychedelic Aftercare

September 24, 2020
Green Market Report reports Mindleap Health has launched a digital health platform that combines telehealth with mood, emotion, and habit tracking.
Read More →
News & Media